Citation Impact
Citing Papers
Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America
2010 Standout
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
2007 Standout
A Phase II Trial of Lutikizumab, an Anti–Interleukin‐1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With Synovitis
2019
Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications
2015 Standout
The re-emergence of natural products for drug discovery in the genomics era
2015 Standout
Human P450 metabolism of warfarin
1997
Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies
2008
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
2014 Standout
Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in rhesus monkeys
1999
Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics
2011
Herb-drug interactions
2000 Standout
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
2008 Standout
Pro-resolving lipid mediators are leads for resolution physiology
2014 StandoutNature
The NLRP3 inflammasome: molecular activation and regulation to therapeutics
2019 Standout
Safety and efficacy of the prostaglandin D2 receptor antagonist AMG 853 in asthmatic patients
2012
Association Between CYP2C9 Genetic Variants and Anticoagulation-Related Outcomes During Warfarin Therapy
2002 Standout
Osteoarthritis: A disease of the joint as an organ
2012 Standout
Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism
2002
Clinical Relevance of the Pharmacokinetic Interactions of Azole Antifungal Drugs with Other Coadministered Agents
2009
Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype
1998
Model-based drug discovery: implementation and impact
2013
IgE and mast cells in allergic disease
2012 Standout
The role of synovitis in osteoarthritis pathogenesis
2012
Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease
2006 Standout
Osteoarthritis
2015 Standout
Fruit juice inhibition of uptake transport: a new type of food–drug interaction
2010
Posaconazole: clinical pharmacology and potential for management of fungal infections
2005
Safety of Long-Term Oral Posaconazole Use in the Treatment of Refractory Invasive Fungal Infections
2006
Pathophysiology of asthma: What has our current understanding taught us about new therapeutic approaches?
2011
The IL-1 family of cytokines and receptors in rheumatic diseases
2019
Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases
2005 Standout
Mould-active azoles: pharmacokinetics, drug interactions in neutropenic patients
2007
Challenges of antibacterial discovery revisited
2010
Targeting multidrug resistance in cancer
2006 Standout
Allergic Rhinitis and Its Impact on Asthma
2001 Standout
Computational design of an enantioselective molecular imprinted polymer for the solid phase extraction of S-warfarin from plasma
2014
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
Aptamers as targeted therapeutics: current potential and challenges
2016 Standout
Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestion
2002
Mechanisms of drug combinations: interaction and network perspectives
2009 Standout
A new high-performance liquid chromatographic method for determination of warfarin enantiomers
2005 StandoutNobel
Antipsychotics and QT prolongation
2003
Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis
2016
Zygomycosis (mucormycosis): emerging clinical importance and new treatments
2004
Antifungal agents – clinical pharmacokinetics and drug interactions
2008
Mechanisms and Functions of Inflammasomes
2014 Standout
Relating protein pharmacology by ligand chemistry
2007 Standout
Pharmacokinetic/Pharmacodynamic Profile of Posaconazole
2010
Etanercept Treatment for Children and Adolescents with Plaque Psoriasis
2008
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
2012
Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'
2004
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
2013 Standout
Pharmacokinetic and Adrenal Interactions of IL‐10 and Prednisone in Healthy Volunteers
1999
Biologic agents in osteoarthritis: hopes and disappointments
2013
Bioluminescent sensor proteins for point-of-care therapeutic drug monitoring
2014 StandoutNobel
Osteoarthritis
2019 Standout
Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis
2018
Pyrazinamide clearance is impaired among HIV/tuberculosis patients with high levels of systemic immune activation
2017 StandoutNobel
Piperacillin-Tazobactam for Pseudomonas aeruginosa Infection: Clinical Implications of an Extended-Infusion Dosing Strategy
2007
Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of escherichia coli, klebsiella pneumoniae, acinetobacter baumannii and pseudomonas aeruginosa from the MYSTIC surveillance program: the OPTAMA Program, South America 2002
2004
Effects of fexofenadine and desloratadine on subjective and objective measures of nasal congestion in seasonal allergic rhinitis
2002
Emerging drugs for the treatment of knee osteoarthritis
2015
Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
2007 Standout
An electrochemical sensor based on multiwall carbon nanotubes and molecular imprinting strategy for warfarin recognition and determination
2014
A Mechanistic Approach to Antiepileptic Drug Interactions
1998
Fingerprinting food: current technologies for the detection of food adulteration and contamination
2012 Standout
Acinetobacter baumannii : Emergence of a Successful Pathogen
2008 Standout
The Effects of Danshen (Salvia miltiorrhiza) on Warfarin Pharmacodynamics and Pharmacokinetics of Warfarin Enantiomers in Rats
1995
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Pharmacokinetics-Pharmacodynamics of Cefepime and Piperacillin- Tazobactam against Escherichia coli and Klebsiella pneumoniae Strains Producing Extended-Spectrum β-Lactamases: Report from the ARREST Program
2003
Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells
1991 Standout
Pharmacokinetics-Pharmacodynamics of Pyrazinamide in a Novel In Vitro Model of Tuberculosis for Sterilizing Effect: a Paradigm for Faster Assessment of New Antituberculosis Drugs
2009
Carbapenemases: the Versatile β-Lactamases
2007 Standout
Triazole antifungal agents drug–drug interactions involving hepatic cytochrome P450
2011
Diagnosis and Treatment of Hip and Knee Osteoarthritis
2021 Standout
Update on the status of DP2 receptor antagonists; from proof of concept through clinical failures to promising new drugs
2013
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
2011 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Effects of Interleukin-1β Inhibition on Incident Hip and Knee Replacement
2020
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death
2015 Standout
Extended-Spectrum β-Lactamases: a Clinical Update
2005 Standout
Posaconazole: A Next-Generation Triazole Antifungal
2007
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
2016 Standout
Pharmacology of Systemic Antifungal Agents
2006
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America
2015 Standout
Three Decades of β-Lactamase Inhibitors
2010 Standout
Knee osteoarthritis has doubled in prevalence since the mid-20th century
2017 Standout
Current status and future prospects for disease modification in osteoarthritis
2017
Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease
2020 Standout
Interleukin-10 and the Interleukin-10 Receptor
2001 Standout
Robust Ligand-Based Modeling of the Biological Targets of Known Drugs
2006
Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America
2008 Standout
Narrative Review: The Promotion of Gabapentin: An Analysis of Internal Industry Documents
2006 Standout
Herbal Modulation of P‐Glycoprotein
2004
Pharmacodynamic Profiling of Piperacillin in the Presence of Tazobactam in Patients through the Use of Population Pharmacokinetic Models and Monte Carlo Simulation
2004
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Clinical Pharmacokinetics and Pharmacodynamics of Warfarin
1986
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis
2020 Standout
Molecular imprinting: perspectives and applications
2016 Standout
Setting and Revising Antibacterial Susceptibility Breakpoints
2007
Works of Christopher Banfield being referenced
Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study
2001
Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive
1995
Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study
2004
Pharmacokinetics of subcutaneously administered etanercept in subjects with psoriasis
2006
Predicting the Drug Interaction Potential of AMG 853, a Dual Antagonist of the D-Prostanoid and Chemoattractant Receptor-Homologous Molecule Expressed on T Helper 2 Cells Receptors
2012
Effects of felbamate on the pharmacokinetics of phenobarbital
1995
Grapefruit Juice Reduces the Oral Bioavailability of Fexofenadine But Not Desloratadine
2002
Population PK and IgE Pharmacodynamic Analysis of a Fully Human Monoclonal Antibody Against IL4 Receptor
2011
Effect of Felbamate on Valproic Acid Disposition in Healthy Volunteers: Inhibition of β‐Oxidation
1996
Application of a Variance-Stabilizing Transformation Approach to Linear Regression of Calibration Lines
1990
A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee
2011
Model‐Based Drug Development: Strengths, Weaknesses, Opportunities, and Threats for Broad Application of Pharmacometrics in Drug Development
2010
Model‐Based Drug Development Survey Finds Pharmacometrics Impacting Decision Making in the Pharmaceutical Industry
2010
Pharmacokinetic Interactions with Felbamate
1997
Use of Preclinical Data for Selection of a Phase II/III Dose for Evernimicin and Identification of a Preclinical MIC Breakpoint
2001
Efficacy and Safety of PF‐06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate
2020
1119 Electrocardiographic effects of multiple high doses of desloratadine
2000
Stereospecific Fluorescence High-Performance Liquid Chromatographic Analysis of Warfarin and its Metabolites in Plasma and Urine
1984
Psychiatry, psychopharmacology and P-450s
1996
Phenylbutazone‐warfarin interaction in man: further stereochemical and metabolic considerations.
1983
Single-Dose, First-in-Human Study of AMG 853: Pharmacokinetics, Pharmacodynamics, and Safety in Healthy Adults
2010
Stereospecific High-Performance Liquid Chromatographic Analysis of Warfarin in Plasma
1983